Company intelligence / Profile preview
Serentis
Cambridge, England, United Kingdomdealbook.nytimes.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Serentis developed a pipeline of products addressing unmet needs in dermatology using a strategy of reprofiling existing drugs and acquiring/licensing near-clinical stage assets. Its lead programs targeted atopic dermatitis and pruritus with novel topical therapies. The company raised over $30 million in venture funding but appears to have ceased operations after 2010, with no evidence of late-stage clinical results or commercial products.
- Therapeutic areas
- OncologyEndocrinologyRare DiseasesDermatology
- Modalities
- Small moleculeTopical therapies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Serentis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Serentis.